Health committee  Thank you for your question. This evening, Health Canada issued an advisory to say that it currently has no safety concerns with Canadian doses. In Europe, they are investigating, but several advisories they have issued say that the side effects were probably not related to the

Health committee  Based on the data we have, I believe there are 30 cases out of 20 million doses. I would have to look at the numbers again. However, we already know that this number of cases is well below the normal incidence of these pathologies. Those cases are linked in time, but not in caus

Health committee  Europe has not reached a consensus on suspension. In the United Kingdom, where the vaccine is most widely used, they have decided not to suspend the use of the vaccine.

Health committee  I'm not aware of any contract details. Those were dealt with by Public Services and Procurement Canada.

Health committee  I'm sorry. I'm not sure I understand the question. The discussions between Health Canada and Pfizer were for the approval, and they continue about ongoing data and safety issues, but the way the doses are administered in the provinces is not a matter that is written—

Health committee  I'm sorry; is that a question?

Health committee  The point I was trying to make before is that those events occur naturally in the population. To make a link between the vaccine and the event, you have to determine if the rate of events is higher than the natural occurrence in the population, which has not been made at this poi

Health committee  The answer is that pharmaceutical products or vaccines are as good on the first date as they are on the last date before the expiry. So, yes, from a quality perspective, it's as good as if it was further from the expiry date.

Health committee  Thank you for your question. Yes, we know the answer to that, and the answer is no, we don't have the same batches here in Canada.

Health committee  That standard has been adopted internationally.

Health committee  The AstraZeneca vaccine has demonstrated 100% efficacy in clinical trials to prevent cases of hospitalization, so there has been evidence of efficacy. On the symptomatic cases, the data was not sufficient, because the number of cases was too small because the number of patients i

Health committee  If I can comment on that, please, the standard of 50% is for the overall efficacy of the vaccine. It's not subject to subpopulation analysis. The overall efficacy of the AstraZeneca vaccine is 62%, and when the doses are spaced, there's some evidence to suggest it could go up to

Health committee  Health Canada's information—

Health committee  I'm sorry.

Health committee  Thank you for your question. As very well explained by Dr. Quach, the clinical trial data is very robust. When you look at the data that was generated for the AstraZeneca vaccine, you see that 24,000 people were in the clinical trials, and the level of severe adverse events that